Breaking News
Sort by:
Top Post
Roche’s Tecentriq Plus Avastin Reduced Risk of Cancer Returning in People with Certain Types of Adjuvant Liver Cancer in a Phase III Study
Roche has announced new data from the Phase III IMbrave050 study that show Tecentriq (atezolizumab) […]
SciTech Development Raises $2.73 Million in Oversubscribed Funding Round to Advance Clinical Trials for Cancer Treatment
SciTech Development has announced it has closed a $2.73M funding round, led by several prominent […]
Eureka Therapeutics Awarded $10.6 Million CIRM Grant to Support Clinical Trial of ARTEMIS® T-Cell Therapy in Pediatric Liver Cancer
Eureka Therapeutics, a clinical-stage biotechnology company developing novel T-cell therapies to treat cancer, today announced […]
FluoGuide Announces Positive Topline Results from Phase IIa Trial of FG001 in Lung Cancer
FluoGuide, a Danish biotech company that pioneers precision cancer surgery, is pleased to announce positive […]
BPGbio Announces First Patients Dosed in Phase 2 Trial of AI-Developed BPM 31510 for Glioblastoma Multiforme
BPGbio, a leading AI-powered biopharma that focuses on oncology, neurology and rare diseases, today announced […]
The Combination of ISA101b and Libtayo® Shows Promising Results in Patients Whose Head and Neck Cancer Progressed on Anti-PD1 Therapy
ISA Pharmaceuticals B.V., a clinical-stage biotechnology company developing immunotherapies to treat cancers and serious infectious […]
GSK Receives US FDA File Acceptance for Jemperli (dostarlimab) plus Chemotherapy for the Treatment of dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer
GSK has announced the US Food and Drug Administration (FDA) accepted the supplemental Biologics License […]
ITM Announces €255m Investment Round, Plans to Advance Radiopharmaceutical Pipeline and to Expand Radioisotope Production Capacities
ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, has announced an equity […]
Exai Bio Presents New Multi-Cancer Early Detection Data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
Exai Bio today announced new data from a 3,300 subject study demonstrating that its novel […]
Promontory Therapeutics Announces Preliminary Data from the National Cancer Institute Phase 2 Clinical Trial of PT-112 in Thymoma and Thymic Carcinoma at 2023 ASCO Annual Meeting
Promontory Therapeutics, a clinical-stage pharmaceutical company advancing small molecule immunotherapies in oncology, announces preliminary data […]
CANbridge Announces Marketing Approval of CAN108 in China for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome
CANbridge Pharmaceuticals, a global biopharmaceutical company, with a foundation in China, committed to the research, […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more